The market is buzzing about Biogen Idec ph1b BIIB-037 data for Alzheimer's disease tomorrow. The press release is coming out at 5:35 am EDT. BIIB represents a 9.72% holding for most common benchmark in biotech, the Nasdaq Biotechnology index, the ETF that tracks this index is IBB. Other ETF's with large exposure include BBH, and PBE.
The data are widely expected to be positive. Either way, it will move the sector. Best of luck.
Data above is from morningstar and etfdb.com
This is the personal blog of Emory Redd.
This blog is not investment advice. This is not a solicitation to invest. Don't take candy from strangers.
BEST OF HEDGEROLL
ACHILLION AND RA CAPITAL: MY FAVORITE TRADE
SALIX INVESTORS LOOKING FOR A BUYOUT SHOULD BE CAUTIOUS; MORE ACCOUNTING PROBLEMS AHEAD
BIOTECH AS BUFFETT'S WONDERFUL BUSINESS